

AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An isolated mutant polypeptide comprising human papillomavirus E6 and E7 polypeptides, wherein the E7 polypeptide has mutations at any one or more of the amino acids corresponding to amino acids 24, 26 or 91 of SEQ ID NO: 14 and the E6 polypeptide has no mutations or has mutations at any one or more of the amino acids corresponding to amino acids 63 or 106 of SEQ ID NO: 13 and the mutant polypeptide retains at least approximately 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7.
2. (Previously Presented) The mutant polypeptide of claim 1 wherein the mutated amino acids are mutated to glycine.
3. (Previously Presented) The mutant polypeptide of claim 1 wherein the E7 polypeptide precedes the E6 polypeptide.
4. (Previously Presented) The mutant polypeptide of claim 2 wherein the E7 polypeptide precedes the E6 polypeptide.
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)

11. (Previously Presented) An immunogenic composition comprising:
 - (a) the mutant polypeptide of claim 1; and
 - (b) a pharmaceutically acceptable carrier.
12. (Original) The immunogenic composition of claim 11 further comprising adjuvant.
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Original) A method for producing an immune response in an individual, which method comprises administering to the individual the immunogenic composition of claim 11 in an amount sufficient to produce the immune response.
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Previously Presented) The isolated mutant polypeptide of claim 1 wherein the E7 polypeptide has mutations in at least two of amino acids corresponding to amino acids 24, 26 and 91 of SEQ ID NO: 14 and the E6 polypeptide has one or more mutations at amino acids corresponding to amino acids 63 and 106 of SEQ ID NO: 13.

22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Previously Presented) The isolated mutant polypeptide of claim 1, wherein the mutant polypeptide retains at least approximately the same immunogenicity as an isolated polypeptide comprising human wild-type papillomavirus E6 and E7.
28. (Previously Presented) The isolated mutant polypeptide of claim 1, wherein the E6 polypeptide has mutations at any one or more of the amino acids corresponding to amino acids 63 or 106 of SEQ ID NO: 13.